News Detail
New Yprk, 27 Jan 2025: Dana-Farber Cancer Institute researchers have identified factors that determine whether donor lymphocyte infusion (DLI), a standard therapy for patients with acute myeloid leukemia (AML) who have relapsed after allogenic hematopoietic stem cell transplant, ......
View Details
Source : Dana-Farber Cancer Institute
cancer immunotherapy
acute myeloid leukemia
immune cells
relapsed AML
T cell population
cancer treatment
Columbia Engineering
Related News
- Solving the drug solubility problem with silica nanoparticles (10-02-2025)
- Revolutionary new cancer treatment destroys tumors in less than 6 days (10-02-2025)
- Nanoparticles damage coronavirus, paving the way for new disinfection technology (02-02-2025)
- Oxford Researchers Develop Method To Identify Fake Covid-19 Vaccines (01-02-2025)
- New drug candidate shows potential to restore vision in people with MS (27-01-2025)
- Research could lead to better medicines and new tools in synthetic biology (25-01-2025)
- Scientists design peptides to enhance drug efficacy (25-01-2025)
- New process for polarity inversion of chemical compounds for precise drug synthesis (22-01-2025)
- Geometric machine learning method promises to accelerate precision drug development (20-01-2025)
- AI-Designed Antivenom Counteracts Toxins from Snakebites (17-01-2025)